Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad.p53-DC vaccine with Nivolumab and Ipilimumab in relapsed SCLC
NCT03406715Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2018
- Primary completion
- Mar 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Ad.p53-DC vaccine in small cell lung cancer (SCLC), sponsored by Moffitt Cancer Center. Primary endpoint: Disease Control Rate at 3 years. Started Mar 2018; status: terminated.
02
Drugs
Ad.p53-DC vaccine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03406715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03406715.